Bifidobacterium animalis lactis + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei + Lactobacillus acidophilus & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Clinical data

• XXX - Bifidobacterium animalis lactis CBT BL3 + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei CBT LC5 + Lactobacillus acidophilus CBT LA1 & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

This randomized, double-blind, placebo-controlled trial revealed that that Bifidobacterium animalis lactis CBT BL3 + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei CBT LC5 + Lactobacillus acidophilus CBT LA1 can positively influence liver health, inflammatory markers, and gut microbiome composition. These could be an effective and safe option that could have place in [Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabol…